HERBALIFE (HLF)

• Herbalife reported Q4 2025 net sales of $1.3 billion, an increase of 6.3% year-over-year, and full-year 2025 net sales of just over $5 billion, up nearly 1%. The company also reduced its total leverage ratio to 2.8x from 3.9x at the end of 2023, having repaid $283 million of debt in 2025.
• For the full year 2026, Herbalife expects reported net sales growth of 1%-6% and adjusted EBITDA in the range of $670 million to $710 million.
• Global sports icon Cristiano Ronaldo acquired a 10% equity stake in HBL Pro2col Software, a Herbalife subsidiary, for $7.5 million, along with a commitment to provide services and sponsorship rights. This partnership is anticipated to elevate the visibility of Herbalife and its Pro2col digital platform, which is expanding its beta program and plans to deliver personalized nutritional supplements by mid-2026.
• India delivered its highest quarterly net sales in Q4 2025, with reported net sales increasing 15% year-over-year, primarily driven by a reduction in the goods and services tax rate.

• Herbalife reported Q4 2025 net sales of $1.3 billion, up 6.3% year-over-year, marking its second consecutive quarter of growth. For the full year 2025, net sales were just over $5 billion, up nearly 1%, and adjusted EBITDA was $658 million.
• The company reduced its total leverage ratio to 2.8x from 3.9x at the end of 2023 and repaid $283 million of debt in 2025.
• For Q1 2026, Herbalife expects net sales growth of 3%-7% and adjusted EBITDA in the range of $155 million to $175 million. For the full year 2026, net sales growth is projected at 1%-6%, with adjusted EBITDA expected between $670 million and $710 million.
• Global sports icon Cristiano Ronaldo acquired a 10% equity stake in HBL Pro2col Software, an Herbalife subsidiary, for $7.5 million, and committed to provide services and sponsorship rights to Pro2col.
• The Pro2col digital health and wellness operating system expanded its beta availability to distributors and customers in the U.S., Canada, and Puerto Rico, with plans to extend to select EMEA markets in 2026.

• Herbalife reported net sales of $1.3 billion for Q4 2025, a 6.3% increase year-over-year, and Adjusted EBITDA of $156 million, a 4.1% increase year-over-year. For the full year 2025, net sales reached $5.0 billion and Adjusted EBITDA was $658 million.
• The company reduced debt by $283 million in 2025, achieving a total leverage ratio of 2.8x as of December 31.
• New distributor growth was up 16% on a two-year stack in Q4 2025, and global sports icon Cristiano Ronaldo invested $7.5 million in Pro2col Software in February 2026.
• For Q1 2026, Herbalife expects net sales to increase by 3.0% to 7.0% year-over-year and Adjusted EBITDA to be between $155 million and $175 million. Full-year 2026 guidance projects net sales growth of 1.0% to 6.0% and Adjusted EBITDA between $670 million and $710 million.

• Herbalife reported Q4 2025 net sales of $1.3 billion, a 6.3% increase year-over-year, and full-year 2025 net sales of just over $5 billion, up nearly 1%.
• Adjusted EBITDA for Q4 2025 was $156 million, and for the full year 2025, it reached $658 million with a 13.1% margin.
• The company reduced its total leverage ratio to 2.8x from 3.9x at the end of 2023, having repaid $283 million of debt in 2025.
• For full-year 2026, Herbalife anticipates reported net sales growth of 1%-6% and adjusted EBITDA between $670 million and $710 million.
• Global sports icon Cristiano Ronaldo acquired a 10% equity stake in HBL Pro2col Software for $7.5 million, aiming to elevate the visibility of Herbalife and Pro2col.

• Herbalife Ltd. reported its financial results for the fourth quarter and full year ended December 31, 2025, with net sales and adjusted EBITDA exceeding guidance. Key financial highlights are presented below:

• The company also provided guidance for the first quarter and full year 2026:

Q1 2026 Guidance

Full-Year 2026 Guidance

• Global sports icon Cristiano Ronaldo invested $7.5 million for a 10% equity stake in HBL Pro2col Software, LLC, an indirect wholly-owned subsidiary of Herbalife.

• Herbalife reported adjusted Q4 non-GAAP EPS of about $0.45 and revenue roughly $1.28–1.30 billion.
• Management provided positive near-term guidance, with a Q1 revenue midpoint of $1.28 billion and FY2026 EBITDA guidance around $690 million.
• The company strengthened its balance sheet in 2025 by cutting debt by $283 million, holding approximately $353 million in cash, and ending the year with a 2.8x leverage ratio.
• Q4 operating margin eased to 7.8% from 8.8% a year prior, while free cash flow margin improved materially to 6.2% from 3.6%.

• Herbalife reported Q4 2025 net sales of $1.3 billion, an increase of 6.3% year-over-year, and full-year 2025 net sales of $5.0 billion, up 0.9% from 2024, with both figures exceeding guidance.
• For Q4 2025, adjusted diluted EPS was $0.45 and adjusted EBITDA was $156.1 million; for the full year 2025, adjusted diluted EPS was $2.12 and adjusted EBITDA was $657.6 million, also surpassing guidance. The company generated $333.3 million in net cash from operating activities for the full year 2025 and maintained a total leverage ratio of 2.8x at December 31, 2025.
• Global sports icon Cristiano Ronaldo invested $7.5 million and secured sponsorship rights for a 10% equity stake in Herbalife's Pro2col Software, LLC in February.
• The company provided Q1 2026 net sales guidance of +3.0% to +7.0% YoY and adjusted EBITDA guidance of $155 million to $175 million, along with full-year 2026 net sales growth of +1.0% to +6.0% YoY and adjusted EBITDA of $670 million to $710 million.

• Herbalife's CEO, Stephan Gratziani, who has been in the role for seven months and was a distributor for over 30 years, is driving the company's strategy to become the "Netflix of health and wellness".
• The company is advancing digital and product personalization with the "Protocol" app (a personal health operating system in beta) and a 51% controlling interest acquisition of Link BioSciences for personalized product formulation, both targeting commercial availability in North America by summer 2026.
• Herbalife has reduced its leverage ratio to 2.8 times (from 3.9 times in March 2024) and prioritizes further debt reduction, aiming for $1.4 billion gross debt by 2028 (a $1 billion reduction from Q2 2024 levels). Share repurchases are not a priority.
• The company expects net sales growth in Q4 2025 and for next year (2026), globally and in the US, building on Q3 2025 growth. Adjusted EBITDA margins have improved from 11.3% in 2023 to north of 13% this year (2025).

• Herbalife is strategically evolving to become the "Netflix of health and wellness" and the world's largest health and wellness platform, moving beyond nutritional supplements to encompass a holistic health picture through data. This includes the Protocol app, a personal health operating system in beta, with full North American commercial availability planned for July next year , and the 51% acquisition of Link BioSciences for personalized product formulation, expected in beta by summer next year.
• The company reported strong Q3 growth globally and in the US, and anticipates global growth in Q4 and next year. Adjusted EBITDA margins are improving, with 11.3% in 2023, 12.7% in 2024, and projected to be north of 13% in 2025.
• Herbalife's primary financial priority is to reduce gross debt by $1 billion to $1.4 billion by 2028, aiming for a leverage ratio below two times by then. The company is a capital-light cash generator, and share repurchases are not a priority.

• Herbalife reported net sales of $1.3 billion, up 2.7% year-over-year, and adjusted EBITDA of $163 million for Q3 2025, exceeding the high end of its guidance range.
• The company achieved worldwide net sales growth of 3.2% on a constant currency basis and North America returned to net sales growth for the first time since Q2 2021.
• Operating cash flows were $139 million, a 40% increase from Q3 2024, and the total leverage ratio was reduced to 2.8 times.
• Herbalife introduced new products and initiatives, including the launch of HL Skin in EMEA, the upcoming commercial launch of Baseline in the US and Puerto Rico, and the acquisition of Linked Bioscience for personalized supplements.
• For the full year 2025, the company updated its guidance, expecting net sales to range from a slight decline of 0.3% to growth of 0.7% (reported) and adjusted EBITDA between $645 million and $655 million (reported).